Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy

Shyam A. Patel1,2, Shakti H. Ramkissoon3, Margarette Bryan1, Lillian F. Pliner1, Gabriela Dontu4, Prem S. Patel5, Sohrab Amiri6, Sharon R. Pine6 & Pranela Rameshwar1

1Department of Medicine – Division of Hematology/Oncology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA, 2Graduate School of Biomedical Sciences, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA, 3Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA, 4Department of Research Oncology, King’s College London School of Medicine, UK, 5Brookdale University Hospital, Brooklyn, NY, USA, 6Department of Medicine – Robert Wood Johnson Medical School and Cancer Institute of New Jersey, New Brunswick, NJ, USA.

The bone marrow (BM) is a major organ of breast cancer (BC) dormancy and a common source of BC resurgence. Gap junctional intercellular communication (GJIC) between BC cells (BCCs) and BM stroma facilitates dormancy. This study reports on a hierarchy of BCCs with the most immature subset (Oct4hi/CD44hi/med/CD24low) demonstrating chemoresistance, dormancy, and stem cell properties: self-renewal, serial passing ability, cycling quiescence, long doubling time, asymmetric division, high metastatic and invasive capability. In vitro and in vivo studies indicated that this subset was responsible for GJIC with BM stroma. Similar BCCs were detected in the blood of patients despite aggressive treatment and in a patient with a relatively large tumor but no lymph node involvement. In brief, these findings identified a novel BCC subset with stem cell properties, with preference for dormancy and in the circulation of patients. The findings establish a working cellular hierarchy of BCCs based on phenotype and functions.

Results

BCC subset with preference for GJIC. We reported on GJIC between BCCs and BM stroma for a dormant phenotype of BCCs. Since not all of the BCCs successfully established GJIC with stroma we sought the identity of
the candidate subset. Three subsets were selected, based on the expression of GFP. The GFP gene was under the control of the Oct4 regulatory region. We selected three subsets, Oct4hi, Oct4med and Oct4lo (Fig. 1A). Oct4 expression is an indicator of pluripotent stem cells. GFP intensity was a surrogate of Oct4 protein (Fig. 1B).

Since GJIC requires the expression of Cxs, we performed western blots for Cx26, Cx32 and Cx43. The band intensities were higher for Cx26 and Cx43 in Oct4hi BCCs (Figs. 1D/S1C). Cx32 was only detected in Oct4hi BCCs. The higher levels of Cxs in Oct4hi correlated with significantly (p<0.05) higher frequency of GJIC with stroma (Fig. S1D/bottom panels, Fig. 1E). Cx43 appeared to be increased in co-cultures of Oct4hi BCCs and stroma (Fig. S1D, top panel). The inhibitor of GJIC, 1-octanol, blunted the labeling for Cx43 (Fig. S1D, top).

The Oct4hi BCCs were highly invasive in vitro and in vivo (Figs. 1F/G; S4D). At 72 h after intravenous injection with 10^3 unsorted pEGFP1-Oct3/4-BCCs, Oct4-expressing BCCs were identified by labeling with PE-anti-cytokeratin (red). Yellow cells (GFP + PE) were noted close to the endosteum, indicating the migration of Oct4hi BCCs (Fig. 1G). The Oct4hi BCCs in the endosteal region

---

**Figure 1** | GJIC by Oct4hi BCCs. A) Selection of BCC subsets with stable transfectants of pEGFP1-Oct3/4. The top and bottom 5% GFP intensities were designated Oct4hi and Oct4lo, respectively and the middle, Oct4med. B) Intracellular flow cytometry for Oct4 protein in Oct4hi and Oct4med subsets. C) Western blots for Oct4 were performed with extracts from unsorted and sorted BCCs. The same blot is also shown for the Oct4 component of Fig. 5E. D) Western blots for Cxs with membrane extracts of BCC subsets. E) The frequency of GJIC with different BCC subsets are shown, mean ± SD, n=4. F) Invasion of BCC subsets and non-tumorigenic MCF12A through matrigel, mean ± SD, n=4. G) BALB/c mice were injected intravenously with 10^3 BCCs, stably transfected with pEGFP1-Oct3/4. After 72 h, the endosteal regions of femurs were examined microscopically (100x) for Oct4 (+) BCCs by labeling with PE-anti-cytokeratin (red). Yellow indicates the merging of PE (red) with GFP (green). H) CFDA-SE-labeled BCCs were injected intravenously and the cells close to the endosteum were labeled for cytokeratin-PE (red). Representative images are shown for Oct4 (-) and Oct4hi BCCs (100x). **p<0.05 vs. other subset; * p<0.05 vs. unsorted and Oct4lo subset.
formed GJIC with endogenous BM cells. This was determined with CFDA-SE (green)-labeled BCCs. The green dye can be seen transferring to another cell, leaving the red-labeled cells. The red label was a result of PE-anti-cytokeratin (Fig. 1H, right panel). The Oct4+ BCCs retained the dye (yellow) (Fig. 1H, left panel).

**Resistance of Oct4hi BCCs to carboplatin.** Oct4hi subset showed preference for GJIC (Fig. 1E). We therefore studied the cells' sensitivity to carboplatin. First, we studied the change in tumor volume by injecting Oct4hi BCC in the dorsal flank of nude BALB/c. When the tumors attained 0.5 cm³, the mice were injected with carboplatin intraperitoneally. Unsorted BCCs succumb to carboplatin at day 8 but Oct4hi remained at ~0.2 cm³ (Fig. 2A). Next, we studied the Oct4hi cells in the BM for sensitivity to carboplatin. Oct4hi BCCs were injected intravenously and then treated with carboplatin at day 2 and 5. The GFP (bright) BCCs were retained close to the endostium, indicating resistance to carboplatin (Fig. 2B).

**Self-renewal of Oct4hi BCCs, in vitro.** This section reported on the self-renewal of Oct4hi BCCs. First, we compared the three BCC subsets for tumorsphere formation and serial passaging. Oct4hi BCCs formed a large tumorsphere as compared to Oct4med BCCs (Fig. S2A). Limiting dilution and serial passaging indicated ~96% efficient tumorsphere formation by Oct4hi BCCs (Figs. 3A, S3A). Oct4med BCCs failed to undergo serial passages.

Next, we examined the GFP intensities of the parental and daughter cells for Oct4hi and Oct4med BCCs. These studies would indicate differences in self-renewal of the two subsets. The results showed similar intensities for the parental and daughter Oct4hi BCCs (Figs. 3C, S3B), supporting self-renewal. Since the half life of Oct4 is ~20 h, the high GFP of the daughter Oct4hi cell indicated constitutive expression of Oct4. In contrast, the GFP intensity of the daughter cell from Oct4med BCCs was significantly lower than the parental (Figs. 3C, S3B).

If Oct4hi BCCs are the most immature cell subset, they should be able to differentiate into heterogeneous subsets. We therefore placed freshly sorted Oct4hi BCCs in culture for 2 wks and then studied the expanded cells for GFP intensity. Indeed, based on the mixed intensity, the results indicated heterogeneity (Fig. 3D). The low GFP intensity was not due to the loss of the vector or confounds of sorting (Figs. S2B/S2C). In order to validate that Oct4hi BCCs can differentiate into different subsets, we used noble agar for colony size because the number of cell/colony is linked to the cell's maturity. Highly proliferating cells will form large colonies and slowly dividing cells are expected to form smaller colonies. We plated one Oct4hi BCC in noble agar. At the first division, we selected the parental and daughter cells (Fig. S3B) and then expand in adherence cultures as for Fig. 3D. After 2 wks, the expanded cells were plated in noble agar. The resulted showed colonies with different number of cells (Figs. S3B/C). In summary, the in vitro studies supported self-renewal of Oct4hi BCCs.

**Serial passage of Oct4hi BCCs, in vivo.** The evidence of self-renewal by in vitro methods (Figs. 3A–D; S3B/C) were validated in serial passages, in vivo. Different numbers of Oct4hi BCCs were injected in the dorsal flanks (P1) of nude BALB/c (n = 10). The time to attain 0.5 cm³ tumors was proportional to the number of injected cells (Fig. S4A). We harvested the tumors from the mice that were injected with 200 Oct4hi BCCs and then selected the Oct4hi cells for passages into naïve mice. The process was repeated three times, totaling four passages (Fig. 3E). Unlike Oct4hi BCCs that can be serially passaged, tumors from Oct4- and Oct4med BCCs regressed after 2 wks (Fig. S4B).

**Division patterns of BCC subsets.** The above studies supported Oct4hi BCCs as functionally immature and with self-renewal ability. We therefore determined if there are differences in cell division and whether this can be supported at the molecular level. Proliferation studies indicated ~3-fold longer doubling time by Oct4hi BCCs as compared to Oct4med BCCs (Fig. S5). This correlated with increases in G1-linked p15 and p16 and decrease in G1/S transition proteins (Cyclin D1 and Cdk 4) (Figs. 4A/S6A). In line with these findings, propidium iodide staining indicated >75% of Oct4hi cells in G0/G1 phase (Fig. 4B).

We next performed time-lapse microscopy of representative bright-field and fluorescence images for Oct4+ (left) and Oct4− (right) parental cells (green arrow), and the progenies of first, second and third divisions as orange, red and blue arrows, respectively (Fig. 4C). The first cell division for Oct4− cell was 7 h and the cell cycle times of the daughter cells were 38 h and 64 h (Movie S1). The 38-h daughter cell divided into three cells with the death of one (yellow X) (Movie S1). The cell cycle rates of the daughters and granddaughters of Oct4− were similar to each other (Fig. 4D, Movie S2): 2 h followed by 30 and 59 h (Movie S2). Asymmetric division of stem cells gave rise to daughters with different proliferative rates22,23. Oct4+ cells showed a significantly longer cycling time as compared to Oct4− cells (mean time = 32 h and 24 h, respectively, p < 0.001) (Fig. 4D). The cycling time of an Oct4− cell varied from 24 to >68 h, whereas Oct4− cell cycle times varied from 20 to 29 h, suggesting that Oct4− cells give rise to daughters with different proliferative rates. Indeed, lineages of live images from multiple cell divisions over 68 h showed similar proliferative rates of Oct4+ progenies but marked differences in the proliferative rates of Oct4− daughters (Figs. 4C/D). Asymmetric cell division was defined as a...
difference in daughter cell cycle length of more than 8 h, or approximately 1/3 the doubling time of the first division. Over 47% of Oct4^{hi} cells asymmetrically divided whereas none of the Oct4^{med} cells divided asymmetrically (Figs. 4E/4F). Of note, none of the several thousand Oct4^{med} cells monitored by time-lapse microscopy became Oct4^{hi} cells (Movie S1), lending further credence to a hierarchical organization of BCC subsets under normal culture conditions.

Gene expression in BCC subsets. Functionally, the Oct4^{hi} BCCs appeared to be stem cells. We therefore analyzed the different subsets for the expression of genes linked to pluripotency. We also determined if there are differences in the expression of hormone receptor in the different subsets. Western blot and flow cytometry indicated high expressions of the drug resistant genes, MDR1 and ABCG2 (Figs. 4G, S6B). The blocker, verapamil, prevented 3-fold exclusion of Hoechst dye in Oct4^{hi} BCCs as compared to no change for the other subsets (Figs. 4H/S7B).

We next examined a larger gene set with arrays and cDNA from Oct4^{hi/med} and Oct4^{med} BCCs (Figs. 5A/B). Ingenuity Pathway analyses with genes having >1.5-fold change in expression, showed a functional network consistent with pluripotency and cell cycle quiescence whereas those with <0.9-fold change in expression indicated cell proliferation (Figs. 5C/D). Together, these networks supported quiescence of Oct4-expressing cells. The array studies were expanded by western blot for stem cell-associated proteins. The results showed an increase in the expression of stem cell genes with extracts from Oct4^{hi} BCCs (Figs. 5E, S1A/B).

Intracellular flow cytometry were performed for estrogen receptor (ER) and progesterone receptor (PR). The resulted showed no change among the different subsets for the triple negative

Figure 3 | Self-renewal of Oct4^{hi} BCCs. A) Serial passages of tumorsphere with 1 Oct4^{hi} cell. B) The frequencies (mean±SD, n = 20) of tumorspheres are shown for unsorted, Oct4^{hi} and Oct4^{med} BCCs. C) The mean±SD (n = 24) GFP intensities are shown for the parental and daughter of Oct4^{hi} and Oct4^{med} BCCs (Fig. S3B). D) Culture of freshly sorted Oct4^{hi} BCCs (left panel, also shown in Fig. 1A) for 2 wks resulted in a heterogeneous population, based on GFP expression (right panel). E) Serial passages of 200 Oct4^{hi} cells were performed in the dorsal flank of nude BALB/c.
MDA-MB-231. However, in the triple positive T47D, heterogeneity was noted with respect to ER/PR expression. A small subset within the Oct4hi T47D was determined to be ER$^2$ (Fig. 5F).

**Phenotype of BCC subsets - cell lines and primary tissues.** Since we used Oct4 as a method to select subsets and there are multiple types of Oct4, we identified the Oct4 type in cell lines and primary BC tissues. Western blots with an antibody that detected all Oct4 types identified Oct4A (45 kDa) in BCCs and undetectable Oct4B and pseudogenes (Fig. 6A). A control for Oct4B used human mesenchymal stem cells and the results indicated predicted bands at 18, 21 and 29 kDa (Fig. 6A)\(^\text{10}\). The increase in Oct4 protein correlated with the respective mRNA (Figs. S8A/B). Immunohistochemical analyses indicated ≈1% Oct4$^+$ in BCC lines (Fig. S8C). Oct4 was detected in malignant and surrounding (Ctrl) breast tissues (Table S1; Fig. 6B); with Oct4$^+$ cells in the highly malignant areas of breast tissues (Fig. 6C). Oct4$^+$/cytokeratin$^+$ cells were identified in the blood of BC patients, including patients who were treated and who had negative lymph node status (Table S2; Fig. 6D). The presence of Oct4 could not be due to pseudogenes since only ≈14% of cytokeratin$^+$ cells from patients with BC were CD44$^+$/CD24$^-$ (Fig. 6E).

**Phenotype of BCC subsets.** CD44$^+$/CD24$^-$/low/lin$^-$ have been reported as markers of BC stem cells\(^\text{17,24}\). In order to analyze all the subsets for CD44 and CD24, we performed flow cytometry with 2-wk cultured Oct4hi BCCs (Fig. 7A). The subset that we identified functionally as stem cells co-expressed CD24 (top/R3) with the upper 5%, CD24$^+$ (middle/R3). The subset that we have identified as non-stem cells were mostly CD24$^-$ (R2; lower/R3). We next analyzed the cells for CD44 in CD24$^-$ BCCs (Fig. 7B).
Figure 5 | Relative gene expressions in BCC subsets. A & B) Taqman Stem Cell Array compared gene expression in Oct4+ and Oct4− MDA-MB-231 (A) and T47D (B). C & D) The output values were normalized to the internal control and then presented as ΔΔCt of Oct4hi/Oct4-. The genes showing >1.5 fold (C) and <0.9 fold (D) differences were analyzed with Ingenuity Pathway Program. E) BCC subsets were studied for stem cell-associated proteins by western blots with nuclear extracts. Notch-1 was analyzed with cytoplasmic extracts. Blots for acetyl-histone H3 and ribosomal protein L28 verified the purity of the compartmentalized extracts. F) Flow cytometry was performed for progesterone (PR) and estrogen (ER) receptors in BCC subsets.
and the results indicated heterogeneity in CD44 expression within Oct4hi and Oct4med BCCs. The results also showed a subset that was CD44dim/Oct4hi (lower box). Oct4hi/CD24 hi BCCs (4%, Fig. 7A; middle/R3) were further analyzed, based on cell size (Fig. 7C, left) and the results showed CD24- cells within the larger subset (R3; right). The phenotypic data were combined

Figure 6 | Oct4 expression in BCCs. A & B) Western blots were performed with whole cell extracts from BCC lines (A) and primary breast tissues: malignant and surrounding (Ctrl) areas (B). The antibody detected all isoforms of Oct4, as shown in the right panel (A). C) Immunohistochemistry with malignant and surrounding normal tissues (Table S1) were stained with hematoxylin and eosin (H&E) (100x) or labeled with anti-Oct4, diaminobenzidine (DAB) and HRP (1000x). D) Flow cytometry with peripheral blood mononuclear cells from BC patients for cytokeratin (PE) and Oct4 (FITC). Shown are the cells within the threshold of PE emission (cytokeratin +) that co-expressed Oct4. The analyses represent 9 subjects (Table S2). E) Cytokeratin (+) cells in the blood of three patients (one Stage 1 and two Stage 3) were analyzed for CD44 and CD24 and the CD44+/CD24- cells (R2) were further studied for Oct4.
with the functional studies to develop a working hierarchy (Fig. 7D).

**Similarity of BCCs in nude mice.** This set of studies determined if the phenotype of the GFP-selected BCCs were retained in vivo. Oct4 hi BCCs, *in vitro*, differentiate in a mixed subset within two weeks (Fig. 3D). We therefore asked if this self-renewal/differentiation occurs in vivo. We selected passage 3 tumors (Fig. 3E) and then analyzed the suspended cells for Oct4 expression by flow cytometry. The results showed a mixed subset (Fig. 3A, top right and lower panels).

Since we found all subsets of the BCCs expressing CD44, we determined if the same occurred when the BCCs were *in vivo*. We therefore injected Oct4− (Fig. S4) and Oct4 hi BCCs (Fig. 3E) and after one and two weeks, respectively, studied the tumors for CD44 expression. In both cases, CD44 was retained in the tumors (Fig. 8B). We next studied the BCCs in the femurs of mice for Oct4 expression, based on GFP. Mice that were injected intravenously with Oct4− and Oct4 hi BCCs. After 5 days, cytokeratin cells were selected and then studied for GFP expression by flow cytometry. Those injected with the former continued to be GFP− (Fig. 8C) whereas those injected with Oct4+ BCCs expressed GFP (Fig. 8D). In
summarized, the cells selected based on GFP retained the same properties in vivo.

Discussion
The identity of BC stem cells remains a subject of investigation. Regardless of the phenotype, it is accepted that BC stem cells express genes linked to pluripotency\(^\text{25,26}\). Among the BCC subsets studied, only Oct4\(^+\) cells initiated tumors without evidence of regression, showed self-renewal property, expressed stem cell genes and divided asymmetrically. Oct4 is expressed at low frequency in BCC lines, and in cellular clusters within the malignant areas of breast tissues (Fig. 6). Regardless of treatment with chemotherapy, Oct4\(^+\)/cytokeratin\(^1\) cells were detected in the blood of BC patients, indicating their resistance to chemotherapy (Fig. 6). We identified Oct4\(^+\)/cytokeratin\(^+\) BCCs in the blood of patients, even when the lymph nodes were negative for BCCs. Although further studies are required, these pilot studies, together with the other findings in this report, suggested that the most immature BCCs may bypass the lymph nodes. In line with these observations, the Oct4\(^+\) BCCs have been shown to rapidly enter the lungs and brain of mice (Fig. S4D). These findings are consistent with the ongoing debate on the benefit of dissecting lymph nodes in BC patients\(^\text{27}\). The Oct4\(^+\) BCCs from cell lines appear to be similar to the cells found in patients (Fig. 6). After the final treatment of patients with triple negative BCCs, the cells in blood were Oct4\((-\)). The similarity of the selected cells with those in vivo (Fig. 8) indicated that the surviving cells in BM, close to the endosteum forming GJIC with endogenous cells (Figs. 1 and 6), could be similar to the resistant BCCs in patients. BCCs show preference for BM where they can resurge after prolong remission for tertiary metastasis with poor outcome\(^\text{28,29}\). The property of the BCCs in BM has not been studied. Our findings suggest that the cells that form GJIC and have tumor-initiating properties could be similar to our selected cells.

Tumor-initiating Oct4\(^+\) BCCs resisted carboplatin and are efficient in establishing GJIC with stroma close to the endosteum (Fig. 1). These findings underscore the significance to BC dormancy and drug resistance. It is unclear if the cycling quiescence of Oct4\(^+\) BCCs caused the cells’ resistance to carboplatin, which requires rapidly dividing cells for effectiveness\(^\text{30}\). Other studies have similarly reported on selective chemoresistance by cancer stem cells\(^\text{31,32}\). The studies in this report will allow us to expand on our previous findings in which we observed the passage of miRNAs through GJIC, a process that facilitates BCC quiescence in BM\(^\text{33}\). The chemoresistance of Oct4\(^+\) BCCs should be taken in the context of the other findings, such as circulating Oct4\((+)\) BCCs in patients and preference for GJIC with stroma. Our studies might provide answers to explain why the BM might be a nidus for cancer resurgence after years of remission\(^\text{27}\) as well as a source of BCC protection\(^\text{34}\). The chemoresistance shown in the in vivo studies and chemosensitivity by the Oct4\(^{-}\)/BCCs are supported by the informatics studies with regards to cell proliferation and quiescence (Fig. 5).

CD44/CD24 has been widely used to isolate BC stem cells\(^\text{17,35,36}\). In our studies, CD44 and CD24 can demarcate cells within the hierarchy, which was established based on function, phenotype and gene expression (Fig. 7). Side population (SP) cells can resist chemotherapy and has been shown to contain the cancer stem cells\(^\text{37,38}\). In our studies, not all Oct4\(^+\) cells effluxed the Hoechst dye and expressed ABCG2 (Figs. 4/S7), suggesting that stem cells might be present in the non-SP subsets. Precedent for this has been reported for glioma cells\(^\text{39}\). ABCG2 does not always correlate with SP since there are 30 proteins within the family.

In summary, we have developed a hierarchy of BCCs, based on function, phenotype and gene expression. The hierarchy forms the impetus for further subdivision based on cell maturity. The expansion of the hierarchy will allow studies on dedifferentiation and to evaluate how BCCs can be efficiently targeted with reduced toxicity. The cells with the least maturity could self-renew and...
undergo serial passages, in vivo. More importantly, we have identified the subset of BCCs that shows functional GJIC with BM stroma and explains dormancy and chemoresistance.

Methods

Isolation of BCC subsets. MDA-MB-231 and T47D were stably transfected with pEGFP-Oct3/4, which expresses green fluorescent protein (GFP) under the control of Oct4 promoter. pEGFP1-Oct3/4 was generously provided by Dr. Wei Cui (Imperial College London, UK). Stable transfectants were obtained with 600 and 400 μg/ml of G418 for MDA-MB-231 and T47D, respectively. Immediately before the assays, subsets were sorted using the FACSDivA (BD Biosciences), based on the intensity of GFP of singlets. The top 5% was designated Oct4+ and the lower 5%, Oct4−. Those between the two extremes were designated Oct4±.

Human subjects. The use of human tissues was approved by the Institutional Review Board of the UMDNJ-Newark Campus and Brookdale University Hospital. Stromal cells were cultured from BM aspirates. Surgical tissues from malignant and normal areas of the breast were obtained from Brookdale University Hospital, NY (Table S1). Peripheral blood was obtained from patients with BC (Table S2).

Tumorpheres assay and in vitro serial passage. BCCs were seeded at 1/well in serum-free media in 96-well low-adhesion plates (Costar, Corning, NY). At day 10, a positive tumorosphere contained >20 cells. One tumorosphere was dissociated with trypsin and then mechanically with a syringe and a 27 gauge needle. The cells were passed through a 40 μm mesh (BD cell strainer cap tube) and then resorted for limiting dilutions at 1 cell/well. This process was repeated 5 times.

Array analyses. Gene expression analyses were performed with Taqman Stem Cell Pluripotency Array (Applied Biosystem), by quantitative RT-PCR, using ABI 7900. The fold change between subsets were calculated using the ΔΔCt method as follows: (ΔΔCtOct4(hi) − ΔΔCtGene of Reference)/(ΔΔCtOct4(lo) − ΔΔCtGene of Reference).

Time-lapse microscopy. Time-lapse microscopy of MDA-MB-231 cells was performed with Axiovert 200 M fluorescence microscope (Carl Zeiss, Inc.) at constant conditions of 37 °C and 5% CO2. Brightfield and fluorescence images were acquired every 10 min for up to 68 h using a 10x objective (Zeiss) and an AxioCam MRm camera with Axiovision software v4.6 (Zeiss). Individual images were adjusted for brightness using the Axiovision software and exported to ImageJ (National Institutes of Health, Bethesda, MD), where the movies were assembled. Individual cells were tracked manually.

In vivo studies. Female athymic BALB/c mice (4 wks) were obtained from Harlan Laboratories (Somerville, NJ) and housed in a laminar flow hood at an AAALAC-accredited facility. The use of mice was approved by the Institutional Animal Care and Use Committee, New Jersey Medical School (Newark, NJ).

Serial passages were performed by injecting different numbers of BCCs in the dorsal flanks of mice. The cells were reseeded in PBS and matrigel at 1:1 ratio in the dorsal flanks of mice. The cells were then labeled by immunocytochemistry for cytokeratin, as described above.

Statistical analyses. Data were analyzed using 2-tailed Student’s t-test, analysis of variance and Tukey-Kramer multiple comparisons test. A p value less than or equal to 0.05 was considered significant.

1. Kakarala, M. & Wicha, M. S. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26, 2813–2820 (2008).

2. Corcoran, K. E. et al. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One 3, e2563 (2008).

3. Rao, G. et al. Facilitating Role of Preprotachykinin-I Gene in the Integration of Breast Cancer Cells within the Stromal Compartment of the Bone Marrow. Cancer Res 64, 2874–2881 (2004).

4. Bodenstein, T. M. et al. Homotypic Gap Junctional Communication Associated with Metastasis Suppression Increases with PKA Activity and Is Unaffected by PI3K Inhibition. Cancer Res 70, 10002–10011 (2010).

5. King, T. J., Fukushima, L. H., Yasui, Y., Lampé, P. D. & Bertram, J. S. Inducible expression of the gap junction protein connexin43 decreases the neoplastic potential of HT-1080 human fibrosarcoma cells in vitro and in vivo. Mol Carcinog 35, 29–41 (2002).

6. Milsom, M. D. & Trumpf, A. Bridging the information gap. Nat Immunol 12, 377–379 (2011).

7. Lincetto, P. K. et al. Gap Junction-Mediated Import of MicroRNA from Bone Marrow Stromal Cells Can Elicit Cell Cycle Quiescence in Breast Cancer Cells. Cancer Res 71, 1550–1560 (2011).

8. Liedtke, S., Stephan, M. & Kogler, G. Oct4 expression revisited: potential pitfalls for data misinterpretation in stem cell research. Biol Chem 389, 845–850 (2008).

9. Zhang, W. et al. Mapping of the minimal internal ribosome entry site element in the human embryonic stem cell gene OCT4b by RNRNA. Biochem Biophys Res Commun 394, 750–754 (2010).

10. Wang, X. & Dai, J. Concise Review: Isofs of OCT4 Contribute to the Confusing Diversity in Stem Cell Biology. Stem Cells 28, 885–893 (2010).

11. Wang, X. Q. et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-akt-ATP-binding cassette G2 pathway. Hepatology 52, 538–539 (2010).

12. Levings, P. P. et al. Expression of an Exogenous Human Oct-4 Promoter Identifies Tumor-Initiating Cells in Osteosarcoma. Cancer Res 69, 5648–5655 (2009).

13. Linn, D. E. et al. A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. Genes Cancer 1, 908–916 (2010).

14. Golann, J. et al. Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res 13, R94 (2011).

15. Kim, R. J. & Nam, J. S. OCT4 Expression Enhances Features of Cancer Stem Cells in a Mouse Model of Breast Cancer. Lab Anim Res 27, 147–152 (2011).

16. Tsai, C. C., Su, P. F., Huang, Y. F., Yew, T. T. & Hung, S. C. Oct4 and Nanog Directly Regulate Dmm1 to Maintain Self-Renewal and Undifferentiated State in Mesenchymal Stem Cells. Mol Cell 47, 169–182 (2012).

17. Al-Hajj, M., Wicha, M. S., ito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983–3988 (1993).

18. Ginevre, C. et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 1, 555–567 (2007).

19. Liu, S. & Wicha, M. S. Targeting Breast Cancer Stem Cells. J Clin Oncol 28, 4006–4012 (2010).

20. Wright, M. et al. Bca1 breast tumors contain distinct CD44+/CD24− and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10, R20 (2008).

21. Greco, S. J., Liu, K. & Rameshwar, P. Functional Similarities Among Genes Regulated by Oct4 in Human Mesenchymal and Embryonic Stem Cells. Stem Cells 25, 3143–3154 (2007).

22. Cicalese, A. et al. The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Ddivisions in Mammary Stem Cells. Cell 138, 1083–1095 (2009).

23. Costa, M. R. et al. Continuous live imaging of adult neural stem cell division and lineage progression in vitro. Development 138, 1057–1068 (2011).

24. Clarke, M. F. et al. Cancer Stem Cells-Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Res 66, 9339–9344 (2006).

25. Hu, T. et al. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res 68, 6533–6540 (2008).

26. Lengerke, C. et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer 11, 42 (2011).

27. Giuliano, A. et al. Auxillary Dissection vs No Auxillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis. JAMA: J Am Med Assoc 305, 569–575 (2011).

28. Alix-Panabieres, C., Riethdorf, S. & Pantel, K. Circulating Tumor Cells and Bone Marrow Micrometastasis. Clin Cancer Res 14, 5013–5021 (2008).

29. Wiedswang, G. et al. Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome. Clin Cancer Res 10, 5342–5348 (2004).

30. Wright, J. A. Principles of chemotherapy. Clin Tech Small Anim Pract 18, 67–72 (2003).

31. Calcagno, A. M. et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 102, 1637–1652 (2010).

32. Honoki, K. et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 24, 501–505 (2010).

33. Pantel, K. & Otte, M. Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. Sem Cancer Biol 11, 327–337 (2001).
34. Patel, S. A. et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 184, 5885–5894 (2010).
35. Cirenajwis, H. et al. Reduction of the putative CD44+ . Anticancer Drugs 21, 897–906 (2010).
36. Wang, K. H. et al. Increasing CD44+/CD24(−) tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Mol Cancer 9, 268 (2010).
37. Hiraga, T., Ito, S. & Nakamura, H. Side population in MDA-MB-231 human breast cancer cells exhibits cancer stem cell-like properties without higher bone-metastatic potential. Oncol Rep 25, 289–296 (2011).
38. Kobayashi, Y. et al. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin. Gynecol Oncol 121, 390–394 (2011).
39. Broadley, K. W. et al. Side Population is not Necessary or Sufficient for a Cancer Stem Cell Phenotype in Glioblastoma Multiforme. Stem Cells 29, 452–461 (2010).
40. Gerrard, L., Zhao, D., Clark, A. J. & Cui, W. Stably transfected human embryonic stem cell clones express OCT4-specific green fluorescent protein and maintain self-renewal and pluripotency. Stem Cells 23, 124–133 (2005).

Acknowledgements
Grant Support: Department of Defense (W81XWH-10-1-0413). This work was done at UMDNJ-New Jersey Medical School, Department of Medicine, Newark, NJ 07103. This work is in partial fulfillment for a Ph.D. degree to Shyam A. Patel.

Author contributions
SAP designed and conducted 90% of the studies; SHR conducted the immunohistochemistry; PSP, MB and LFP interpreted the data and designed the studies with human blood; GD designed the self-renewal studies; SA and SRP performed the time lapse studies and interpreted the results; PR conceptualized the entire study, designed and interpreted the results. All authors were involved in writing the manuscript.

Additional information
Supplementary information accompanies this paper at http://www.nature.com/scientificreports

Competing financial interests: The authors declare no competing financial interest.

License: This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

How to cite this article: Patel, S.A. et al. Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Sci. Rep. 2, 906; DOI:10.1038/srep00906 (2012).